# Jones Hill Capital LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 2102314. Source: https://holderbook.com/funds/2102314-jones-hill-capital-lp/

- Reported value: $470.4M
- Positions: 29
- Weight of the ten largest: 68.8%
- Filed: 2026-08-13

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC | [BMRN](https://holderbook.com/stocks/BMRN/) | $81.9M | 1,431,590 | 17.4% | 2 |
| GILEAD SCIENCES INC | [GILD](https://holderbook.com/stocks/GILD/) | $43.3M | 343,043 | 9.2% | 1 |
| ARCUTIS BIOTHERAPEUTICS INC | [ARQT](https://holderbook.com/stocks/ARQT/) | $28.6M | 1,089,701 | 6.1% | 1 |
| MADRIGAL PHARMACEUTICALS INC | [MDGL](https://holderbook.com/stocks/MDGL/) | $28.2M | 52,545 | 6.0% | 1 |
| BICARA THERAPEUTICS INC | [BCAX](https://holderbook.com/stocks/BCAX/) | $26.5M | 892,621 | 5.6% | 2 |
| RELMADA THERAPEUTICS INC | [RLMD](https://holderbook.com/stocks/RLMD/) | $25.3M | 3,655,075 | 5.4% | 2 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $25.0M | 1,339,212 | 5.3% | 2 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $23.4M | 677,879 | 5.0% | 2 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $22.2M | 367,900 | 4.7% | 1 |
| ANI PHARMACEUTICALS INC | [ANIP](https://holderbook.com/stocks/ANIP/) | $19.4M | 233,808 | 4.1% | 2 |
| IMMUNOCORE HLDGS PLC | [IMCR](https://holderbook.com/stocks/IMCR/) | $16.3M | 512,856 | 3.5% | 1 |
| AMYLYX PHARMACEUTICALS INC | [AMLX](https://holderbook.com/stocks/AMLX/) | $16.1M | 894,058 | 3.4% | 2 |
| INSMED INC | [INSM](https://holderbook.com/stocks/INSM/) | $13.0M | 122,375 | 2.8% | 1 |
| NUVALENT INC | [NUVL](https://holderbook.com/stocks/NUVL/) | $12.2M | 98,442 | 2.6% | 2 |
| CAPRICOR THERAPEUTICS INC | [CAPR](https://holderbook.com/stocks/CAPR/) | $10.1M | 420,751 | 2.2% | 2 |
| ACLARIS THERAPEUTICS INC | [ACRS](https://holderbook.com/stocks/ACRS/) | $9.3M | 1,759,492 | 2.0% | 1 |
| IMMUNIC INC | [IMUX](https://holderbook.com/stocks/IMUX/) | $8.3M | 539,814 | 1.8% | 1 |
| ORIC PHARMACEUTICALS INC | [ORIC](https://holderbook.com/stocks/ORIC/) | $8.1M | 747,313 | 1.7% | 1 |
| TONIX PHARMACEUTICALS HLDG C | [TNXP](https://holderbook.com/stocks/TNXP/) | $8.0M | 625,428 | 1.7% | 2 |
| SYNDAX PHARMACEUTICALS INC | [SNDX](https://holderbook.com/stocks/SNDX/) | $7.4M | 340,000 | 1.6% | 1 |
| OLEMA PHARMACEUTICALS INC | [OLMA](https://holderbook.com/stocks/OLMA/) | $7.2M | 574,166 | 1.5% | 1 |
| VIR BIOTECHNOLOGY INC | [VIR](https://holderbook.com/stocks/VIR/) | $6.7M | 659,213 | 1.4% | 2 |
| CORBUS PHARMACEUTICALS HLDGS | [CRBP](https://holderbook.com/stocks/CRBP/) | $6.1M | 653,572 | 1.3% | 1 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $5.6M | 57,100 | 1.2% | 1 |
| VERTEX PHARMACEUTICALS INC | [VRTX](https://holderbook.com/stocks/VRTX/) | $5.5M | 11,123 | 1.2% | 2 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $2.5M | 49,850 | 0.5% | 2 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $2.2M | 40,567 | 0.5% | 2 |
| PHATHOM PHARMACEUTICALS INC | [PHAT](https://holderbook.com/stocks/PHAT/) | $1.8M | 161,486 | 0.4% | 1 |
| ACHIEVE LIFE SCIENCE INC | [ACHV](https://holderbook.com/stocks/ACHV/) | $174.7K | 26,760 | 0.0% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +15.9% | +14.8% | +1.1% | 94% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $470.4M | 29 |
| Q1 2026 | $466.5M | 26 |